ISS Recommends Shareholders Vote 'FOR' Bristol-Myers Squibb (BMY)/Celgene (CELG) Deal

(Updated - March 29, 2019 9:34 AM EDT)

In an e-mail to StreetInsider.com, Bristol-Myers Squibb (NYSE: BMY) confirmed that ISS recommended voting in favor of the Celgene (NASDAQ: CELG) deal.

Highlights from ISS

• strategic rationale is 'is sound'.
• replenishes BMY's late-stage pipeline, diversifying its exposure to its top drug (Opdivo)
• CELG's patent cliff was known in the market
• valuation "appears reasonable"
• seems to be no evidence to suggest that a buyer will be waiting on the other side of a broken deal to acquire BMY
• For BMY, the standalone scenario seems highly challenged.

You May Also Be Interested In

• IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B
• PENN Entertainment (PENN) Climbs after Hedge Fund Greenlight Takes Stake
• Bunge (BG) PT Raised to $122 at Citi